1 Ocak 2022 Dergi makalesi Açık Erişim

Kalkanli Tas, Sevgi; Uzunoglu, Merve Saide; Uzunoglu, Aylin Seher; Kirkik, Duygu; Altunkanat, Derya; Kalkanli, Nevin

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/256005</identifier>
  <creators>
    <creator>
      <creatorName>Kalkanli Tas, Sevgi</creatorName>
      <givenName>Sevgi</givenName>
      <familyName>Kalkanli Tas</familyName>
      <affiliation>Univ Hlth Sci, Hamidiye Med Fac, Dept Immunol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Uzunoglu, Merve Saide</creatorName>
      <givenName>Merve Saide</givenName>
      <familyName>Uzunoglu</familyName>
      <affiliation>Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Uzunoglu, Aylin Seher</creatorName>
      <givenName>Aylin Seher</givenName>
      <familyName>Uzunoglu</familyName>
      <affiliation>Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kirkik, Duygu</creatorName>
      <givenName>Duygu</givenName>
      <familyName>Kirkik</familyName>
      <affiliation>Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Altunkanat, Derya</creatorName>
      <givenName>Derya</givenName>
      <familyName>Altunkanat</familyName>
      <affiliation>Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kalkanli, Nevin</creatorName>
      <givenName>Nevin</givenName>
      <familyName>Kalkanli</familyName>
      <affiliation>Diyarlife Hosp, Dept Dermatol, Diyarbakir, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Adoptive T-Cell Therapies To Overcome T Cell-Dependent Immune Dysregulations In Covid-19</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2022</publicationYear>
  <dates>
    <date dateType="Issued">2022-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/256005</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.55730/1300-0152.2579</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.</description>
  </descriptions>
</resource>